Results 61 to 70 of about 2,821 (202)
Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy [PDF]
Investigative and Clinical Urology, 2017 Purpose: We aimed to assess the patient-reported outcome (PRO) and efficacy of add-on low-dose antimuscarinic therapy in overactive bladder (OAB) patients with suboptimal response to 4-week treatment with beta 3 agonist monotherapy (mirabegron, 50 mg).
Jung Hyun Shin, Aram Kim, Myung-Soo Choo
doaj +1 more source
, 2018 Table S4. Summary of adherence with mirabegron compared with antimuscarinics in subgroups defined by treatment experience, age and gender.
Jameel Nazir (3831556) +6 more
core +1 more source
Neurourology and Urodynamics, Volume 45, Issue 8, Page 1545-1555, November 2026.ABSTRACT Objective To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT‐A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). Methods A systematic review and meta‐analysis with parallel synthesis of two distinct interventions was conducted of randomized and ...
Hussain Arshad +4 more
wiley +1 more source
Advancing Personalized Care for Neurogenic Bladder: The Case for Continent Urinary Diversion
Neurourology and Urodynamics, Volume 45, Issue 8, Page 1489-1492, November 2026.ABSTRACT Introduction Neurogenic lower urinary tract dysfunction (NLUTD) with a poorly compliant bladder that is refractory to minimally invasive therapies (MIT) represents an “end‐stage” phenotype in which the principal objectives are durable upper urinary tract protection and restoration of continence with acceptable long‐term morbidity.
Francis A. Jefferson, Maude E. Carmel
wiley +1 more source
Drugs - Real World Outcomes, 2020 Background Emergency department (ED) visits or hospitalizations should prompt review of the patient’s medications after discharge and targeted deprescribing to reduce ongoing risks.
Ariel R. Green +4 more
doaj +1 more source
, 2018 Table S3. Summary of adherence with mirabegron compared with antimuscarinics in subgroups defined by the target OAB drug received.
Jameel Nazir (3831556) +6 more
core +1 more source
Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies
European Journal of Clinical Investigation, Volume 56, Issue 10, October 2026.COPD is a heterogeneous disease driven by overlapping neutrophilic and eosinophilic inflammatory pathways. This review highlights the shift from symptom‐based treatment toward phenotype‐ and biomarker‐directed care. Blood eosinophils, FeNO, and IgE predict corticosteroid responsiveness and identify candidates for biologic therapy.
Sasha Raman +3 more
wiley +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.This review charts the evolution of cholinergic therapies for neurodegenerative diseases—from classical acetylcholinesterase inhibitors (AChEIs) providing symptomatic relief to precision multi‐target drugs and neuromodulation (VNS, DBS, NIBS) that restore dysfunctional circuits. Emerging gene therapy, cell regeneration, and advanced cholinergic imaging
Lei Lei +4 more
wiley +1 more source
Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
Therapeutic Advances in Urology, 2022 Background: Antimuscarinics (AMs) represent the mainstay of treatment for storage lower urinary tract symptoms (LUTS) but few data are available on their impact in multiple sclerosis (MS) patients.
Elena Andretta +5 more
doaj +1 more source
Mirabegron - a selective β3-adrenoreceptor agonist for the treatment of overactive bladder. [PDF]
, 2012 15.04.14 KB. Ok to add published version to Spiral, OA paperOveractive bladder is a common condition that significantly impacts overall quality of life.
Digesu, GA +3 more
core +1 more source